GAITHERSBURG, Md., May 28, 2015 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) today announced that its president and CEO, Douglas J. Swirsky, will present a company overview at the Jefferies 2015 Global Healthcare Conference at 11 a.m. EDT on Thursday, June 4, 2015.
The live and archived webcast of Mr. Swirsky's presentation will be available at the following link: http://wsw.com/webcast/jeff88/gnvc. This link will also be available on GenVec's website. To access, visit www.genvec.com, click on "Investors and Media" and select the "Presentations" option under the "News/Events" menu. The webcast replay will be accessible for 90 days.
GenVec is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging its proprietary adenovector gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec's lead product candidate, CGF166, is licensed to Novartis and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, we also focus on opportunities to license our proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
Contact: GenVec, Inc. Rena Cohen (240) 632-5501 firstname.lastname@example.org
SOURCE GenVec, Inc.